Somaxon Pharmaceuticals — Technical Presentation (June 2008)
6 slides from Somaxon Pharmaceuticals's technical presentation, Jun 12, 2008
Slide 1: Figure 2. CGI-Improvement at Baseline, After 2 Weeks and After 12 Weeks
Note: Severity categories included: Normal, Very Mild, Mild, Moderate, Marked, Severe, and Extremely Severe. Figure 2. CGI-Improvement at Baseline, After 2 Weeks and After 12 Weeks (Study A)
Slide 2: Figure 3. % of Subjects on CGI-Improvement with Moderate to Marked Improvement
Note: Improvement categories included: Marked Improvement, Moderate Improvement, Minimal Improvement, Unchanged, Minimal Worsening, Moderate Worsening, and Marked Worsening. Figure 3. % of Subjects on CGI-Improvement with Moderate to Marked Improvement (Study A)
Slide 3: Figure 4. PGI Items After 12 Weeks
Figure 4. PGI Items After 12 Weeks (Study A)
Slide 4: Figure 5. % of Subjects on PGI Indicating Study Medication Helped Sleep
Figure 5. % of Subjects on PGI Indicating Study Medication Helped Sleep (Study A)
Slide 5: Figure 6. PGI Items at Final Study Visit (Study B)
Figure 6. PGI Items at Final Study Visit (Study B)
Slide 6: Safety Results
SAFETY RESULTS Rates of treatment-emergent AEs were comparable across groups in both Study A (PBO=52%; DXP 1 mg=40%; DXP 3 mg=38%) and Study B (PBO=27%; DXP 6 mg=31%). There were two AEs reported by ³ 5% of subjects, headache in Study A (PBO=14%; DXP 1 mg=3%; DXP 3 mg=6%) and somnolence/sedation in
Somaxon Pharmaceuticals — Technical Presentation (June 2008) on 6ix